Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on January 17th, 2019 by Janet HuangPharma R&D
Here at Sigilon Therapeutics, we have had a very exciting period of growth recently, including receiving an Advanced Therapy Medicinal Product (ATMP) designation from the European Medicines Agency, adding two new members to our leadership team and initiating a collaboration with Eli Lilly in type 1 diabetes. (more…)
Posted on January 17th, 2019 by Xuanyan XuPharma R&D
The partial shutdown of the U.S. government, which began just before the Christmas holiday, has been especially terrible for hundreds of thousands of federal employees who are either furloughed or working without pay. (more…)
Posted on January 17th, 2019 by Shawn HooksPharma R&D
Pharma R&D costs continue to rise rapidly. A well-known Tufts study estimated the average pre-tax cost per new approved prescription drug (including failures and capital costs) was nearly $2.6 billion in 2013. However, the creation of novel approved drugs has not kept up with investment over the past two decades. (more…)
Posted on January 15th, 2019 by Xuanyan XuPharma R&D
In the pharmaceutical industry, safety protocols are rigorous. Clinical trials, a lengthy and intense part of the drug development process, are deemed absolutely crucial to ensuring the safety and efficacy of new drugs and therapies. There are also many regulations designed to make certain that high standards are maintained during the various trial phases.
Posted on January 15th, 2019 by Nicki CatchpolePharma R&D
2019 marks the 37th year of the J.P. Morgan Healthcare Conference, which has come to be one of the premiere annual events for companies involved in all aspects of the industry, from biotech start-ups to large healthcare service providers. (more…)
Posted on December 12th, 2018 by Nicki CatchpolePharma R&D
Innovation used to be almost solely accredited to Big Pharma, but many of the more established businesses in the industry are finding that their rate of discovery is slowing as they try to find answers to some the industry’s biggest problems, such as antibiotic resistance. (more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.